| Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2018: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2017: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2016: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Outline of Final Research Achievements |
This study aimed to investigate the efficacy of cancer immunotherapy in treating pediatric brain tumor. Based on the evaluation of pediatric brain tumor tissue samples and the results of tumor-associated antigen based vaccine therapy for pediatric oncological diseases, including brain tumors, the induction of cancer antigen-specific cytotoxic T cells is considered to be an important strategy for treating pediatric brain tumors. However, a good antitumor effect was also observed among the T cells expressing the chimeric antigen receptor. Therefore, we proposed to improve antitumor efficacy by applying the chimeric antigen receptor to brain tumor-specific cytotoxic T cells.
|
